Literature DB >> 23996636

Purification of GidA protein, a novel topoisomerase II inhibitor produced by Streptomyces flavoviridis.

Antony K Teresa Infanta S1, S D Nisshanthini, M Palaniswamy, J Angayarkanni.   

Abstract

The presence of topoisomerase II inhibition activities in the intracellular extract of Streptomyces flavoviridis was investigated. One active compound inhibiting relaxation activity of topoisomerase II was determined to be a protein. This active principle was purified to homogeneity by gel filtration followed by ion exchange chromatography. The apparent molecular mass was 42 kDa as determined by SDS-PAGE. MALDI TOF peptide mass fingerprinting analysis confirmed this topoisomerase II inhibitor, as glucose-inhibited division protein A (GidA) by MOWSE score of 72. The effects of purified GidA protein on DNA relaxation and decatenation by topoisomerase II were investigated. It inhibited topoisomerase II activity and acted as a topoisomerase poison that significantly stabilized the covalent DNA-topoisomerase II reaction intermediate "cleavable complex", as observed with etoposide. Collectively, these findings indicate that GidA is a potent inhibitor of topoisomerase II enzyme, which can be exploited for rational drug design in human carcinomas.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23996636     DOI: 10.1007/s11274-013-1475-1

Source DB:  PubMed          Journal:  World J Microbiol Biotechnol        ISSN: 0959-3993            Impact factor:   4.253


  46 in total

1.  Selection of cancer chemopreventive agents based on inhibition of topoisomerase II activity.

Authors:  K H Cho; J M Pezzuto; J L Bolton; V E Steele; G J Kelloff; S K Lee; A Constantinou
Journal:  Eur J Cancer       Date:  2000-10       Impact factor: 9.162

2.  A gel electrophoresis assay for the simultaneous determination of topoisomerase I inhibition and DNA intercalation.

Authors:  Michael R Webb; Susan E Ebeler
Journal:  Anal Biochem       Date:  2003-10-01       Impact factor: 3.365

3.  Peptides based on CcdB protein as novel inhibitors of bacterial topoisomerases.

Authors:  Eliane Trovatti; Camila A Cotrim; Saulo S Garrido; Ronaldo S Barros; Reinaldo Marchetto
Journal:  Bioorg Med Chem Lett       Date:  2008-10-07       Impact factor: 2.823

Review 4.  Clinical applications of anticancer drugs targeted to topoisomerase II.

Authors:  K R Hande
Journal:  Biochim Biophys Acta       Date:  1998-10-01

5.  Covalent bonds between protein and DNA. Formation of phosphotyrosine linkage between certain DNA topoisomerases and DNA.

Authors:  Y C Tse; K Kirkegaard; J C Wang
Journal:  J Biol Chem       Date:  1980-06-25       Impact factor: 5.157

6.  P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.

Authors:  A G van der Zee; H Hollema; S de Jong; H Boonstra; A Gouw; P H Willemse; J G Zijlstra; E G de Vries
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

7.  The DNA/RNA-binding protein, TB-RBP, moves from the nucleus to the cytoplasm and through intercellular bridges in male germ cells.

Authors:  C R Morales; X Q Wu; N B Hecht
Journal:  Dev Biol       Date:  1998-09-01       Impact factor: 3.582

8.  The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex.

Authors:  T G Gantchev; D J Hunting
Journal:  Mol Pharmacol       Date:  1998-03       Impact factor: 4.436

9.  Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.

Authors:  Jae Sung Kim; George P Amorino; Hongryull Pyo; Qianwen Cao; Hak Choy
Journal:  Radiother Oncol       Date:  2002-01       Impact factor: 6.280

10.  DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells.

Authors:  S J Falk; P J Smith
Journal:  Int J Radiat Biol       Date:  1992-06       Impact factor: 2.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.